Biohit Oyj (LTS:0DRP) Margin of Safety % (DCF Earnings Based): N/A (As of Jun. 26, 2026)


LTS:0DRP Biohit Oyj LTS:0DRP
78 GF Score
Price €2.47
GF Value €2.69
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Biohit Oyj Margin of Safety % (DCF Earnings Based)?

Margin of Safety % (DCF Earnings Based) = (Intrinsic Value: DCF (Earnings Based) - Current Price) / Intrinsic Value: DCF (Earnings Based).

Note: Discounted Earnings model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Biohit Oyj's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Earnings Based) is not calculated.

LTS:0DRP vs ABT, SYK, MDT: Margin of Safety % (DCF Earnings Based) Comparison

For the Medical Devices subindustry, Biohit Oyj's Margin of Safety % (DCF Earnings Based), along with its competitors' market caps and Margin of Safety % (DCF Earnings Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Biohit Oyj Margin of Safety % (DCF Earnings Based) vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Biohit Oyj's Margin of Safety % (DCF Earnings Based) distribution charts can be found below:

* The bar in red indicates where Biohit Oyj's Margin of Safety % (DCF Earnings Based) falls into.


LTS:0DRP
78GF Score
Biohit Oyj LTS:0DRP
Margin of Safety % (DCF Earnings Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Biohit Oyj (LTS:0DRP) Overvalued in 2026?

Based on GuruFocus' analysis, Biohit Oyj stock appears to be undervalued. The current stock price of €2.47 is trading 8.4% below its estimated GF Value™ of €2.69. GuruFocus considers Biohit Oyj to be Fairly Valued.

Key valuation signals for LTS:0DRP:

  • Margin of Safety % (DCF Earnings Based): N/A
  • GF Value™: €2.69 vs. price of €2.47 (8.4% below fair value)
  • GF Score™: 78/100 with 4 warning signs

No single metric tells the full story. See the LTS:0DRP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Biohit Oyj Business Description

Other Exchanges BIOBV:Finland
Address Laippatie 1, Helsinki, FIN, 00880
Biohit Oyj is a globally operating Finnish biotechnology company that develops diagnostic and other health products. Its products include GastroPanel quick test assesses the structure and function of the stomach lining; ColonView quick test is an immunochemical fecal occult blood test (FIT) developed; Acetium capsules protect the stomach lining from carcinogenic acetaldehyde, especially in people with acid-free stomachs. The company's product portfolio consists of diagnostic tests, analysis systems, products binding carcinogenic acetaldehyde into a harmless compound and monoclonal antibodies.
78GF Score

Get the complete analysis for LTS:0DRP

Margin of Safety % (DCF Earnings Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.47
Price
€2.69
GF Value